Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease

Mark C. Walters, University of California San Francisco
Laura M. De Castro, University of Pittsburgh
Keith M. Sullivan, Duke University
Lakshmanan Krishnamurti, Emory University
Naynesh Kamani, AABB
Christopher Bredeson, University of Ottawa
Donna Neuberg, Dana Farber Cancer Institute
Kathryn L. Hassell, University of Colorado
Stephanie Farnia, National Marrow Donor Program
Andrew Campbell, University of Michigan

Only first 10 authors above; see publication for full author list.

Final published version: http://dx.doi.org/10.1016/j.bbmt.2015.10.017

Copyright information:
© 2016 American Society for Blood and Marrow Transplantation. This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease

Mark C. Walters 1,*, Laura M. De Castro 2, Keith M. Sullivan 3, Lakshmanan Krishnamurti 4, Naynesh Kamani 5, Christopher Bredeson 6, Donna Neuberg 7, Kathryn L. Hassell 8, Stephanie Farnia 9, Andrew Campbell 10, Efie Petersdorf 11

1 Blood and Marrow Transplant Program, University of California (San Francisco) Benioff Children’s Hospital, Oakland, California
2 Division of Hematology and Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
3 Blood and Marrow Transplant Program, Duke University Medical Center, Durham, North Carolina
4 Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University, Atlanta, Georgia
5 Center for Cellular Therapies and Research, AABB, Bethesda, Maryland
6 Blood and Marrow Transplant Program, Ottawa Hospital Research Institute at University of Ottawa, Ottawa, Ontario, Canada
7 Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
8 University of Colorado School of Medicine, Aurora, Colorado
9 National Marrow Donor Program, Minneapolis, Minnesota
10 Division of Pediatric Hematology/Oncology, University of Michigan, School of Medicine, Department of Pediatrics, Blood and Marrow Transplant Program, Ann Arbor, Michigan
11 Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, Washington

ABSTRACT

Although a number of published trials exist of HLA-identical sibling hematopoietic cell transplantation (HCT) for sickle cell disease (SCD) that span 2 decades, when and for whom this therapy should be pursued is a subject of debate. Assessments of the therapeutic value of HLA-identical sibling HCT for children with SCD and serve as the basis for a strong recommendation in favor of the option of HCT when a suitable donor is available. The experience of HLA-identical sibling HCT in adults with SCD is limited but appears to be similar to results in children. These preliminary observations, however, warrant further investigation.

© 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

INTRODUCTION

Hematopoietic cell transplantation (HCT) for sickle cell disease (SCD) is curative in most individuals who receive this treatment, but it is a treatment option that very few families and patients pursue [1-4]. The principal reason why so few transplants are performed is that most affected people lack a suitable donor. Even so, it is estimated that 18% of affected individuals will have an HLA-identical (HLA-ID) sibling donor [5]. Yet, far less than 1% of the SCD population in the United States has received a transplant. Many barriers to transplant exist, and these are detailed in other reports [6-8]. A key barrier is a prevailing assumption that HCT is risky and carries a mortality rate that exceeds mortality experienced with a supportive care approach. In addition, there are risks of infertility and of graft-versus-host disease (GVHD), which can cause a chronic debilitating disorder.
In this brief review the basis for assumptions about mortality risk is examined in an update of the contemporary experience of HLA-ID sibling HCT for SCD.

An important benefit of successful HCT is the elimination of sickle erythropoiesis, thereby significantly reducing, or in most instances, ending the risk of sickle-related complications [9,10]. Thus, most agree that quality of life after successful HCT should be very much improved compared with that in individuals who continue to live with SCD. These comparisons about protection from sickle-related damage are difficult because prospective comparisons between groups of subjects treated by HCT and by supportive care have never been conducted. Thus, most analyses rely on comparisons with historical control subjects, which weakens their impact. In addition, some recipients have experienced events soon after HCT, such as pain, intracranial hemorrhage, and infection. Thus, protection is not universal in those who survive with engraftment of donor cells, although these events eventually resolve. For these reasons the benefit of HCT with regard to symptom abatement and organ function is not the focus of this review. However, the importance of conducting studies that systematically monitor prospective outcomes in comparison cohorts that might establish unequivocal indications for HCT cannot be overstated.

**HCT IN CHILDREN WITH SCD**

In developing eligibility criteria for HCT in early studies, investigators selected clinical features of SCD that carry a high burden of ongoing supportive care with a risk of cumulative organ injury and an association with early mortality [11]. In childhood, supportive care delivered at comprehensive sickle cell centers is currently associated with excellent survival to adulthood, with a risk of mortality before age 18 that ranges from 1% to 2% by age 20 in the East London Cohort to 6.1% in the Dallas Newborn Cohort [12,13]. Thus, transplantation studies in childhood focused initially on minimizing the risks of early transplant-related death and of sickle-related clinical complications after successful transplantation. Currently, HCT in children with SCD is typically restricted to those with a clinical stroke or who have experienced recurrent vaso-occlusive complications such as pain and/or acute chest syndrome despite receiving optimal supportive care. The eligibility criteria used in the largest pediatric clinical trials completed 10 to 15 years ago are presented in Table 1. In the current era as the survival rates in transplant and nontransplant cohorts converge, restricting HCT solely in children who have had a significant complication such as stroke is no longer appropriate, as suggested below. A liberalized approach to indications for HCT would also increase its utilization.

**Table 1**

<table>
<thead>
<tr>
<th>Indications for HCT in Children with SCD (HbSS or HbS–β-thalassemia)</th>
</tr>
</thead>
<tbody>
<tr>
<td>One or more of the following complications:</td>
</tr>
<tr>
<td>Stroke or central nervous system event lasting longer than 24 hours</td>
</tr>
<tr>
<td>Impaired neuropsychological function with abnormal cerebral magnetic resonance imaging and angiography</td>
</tr>
<tr>
<td>Recurrent acute chest syndrome</td>
</tr>
<tr>
<td>Stage I or II sickle lung disease (defined in [14])</td>
</tr>
<tr>
<td>Recurrent vaso-occlusive painful episodes or recurrent priapism</td>
</tr>
<tr>
<td>Sickle nephropathy (glomerular filtration rate 30%–50% of predicted normal)</td>
</tr>
</tbody>
</table>

A compilation of the most recent single-center patient series in children with SCD treated by HLA-ID sibling HCT is presented in Table 2. In a series of 40 patients treated in Rome, Italy, the rates of overall survival and event-free survival (EFS) were both 91% after an HLA-ID sibling bone marrow transplantation (BMT) with a conventional preparative regimen of busulfan (BU)/cyclophosphamide/horse antithymocyte globulin (ATG) with or without fludarabine (Flu) [15]. In a series from Belgium, 37 of 38 children treated since 1995, who also received hydroxyurea (HU) well before HCT, survived free of SCD with an 8-year estimate of EFS of 97.1% [16]. In a series of children treated in New York who received a combination of BU, Flu, and alemtuzumab (Alem) before HLA-ID sibling HCT, all 18 children survived free of SCD after HCT [17]. Another single-center series from Atlanta observed 24 of 25 patients who were treated by HLA-ID sibling HCT between 1993 and 2007, after preparation with BU/cyclophosphamide/horse ATG, who survived free of SCD [19]. A recent multicenter investigation of 43 children with SCD who received Alem/Flu/melphalan before HLA-ID sibling BMT reported survival and EFS probabilities of 93% and 90.7%, respectively [21]. Finally, the experience from Pavia was also recently reported in which all 30 recipients survived after HLA-ID HCT after preparation with BU/thiotepa/Flu or treo-sulfan/thiotepa/Flu and ATG [20]. Together these combined series include 218 recipients, of whom 208 (95%) survived after transplantation and 200 (92%) survived free of SCD. These updated published results strongly suggest that survival after HCT from an HLA-ID sibling in children with SCD is not inferior to survival among those treated by standard supportive care. At last follow-up only 6 survivors (3%) were receiving immunosuppressive therapy to treat chronic GVHD.

Similar results have been reported from transplant registry data where there are approximately 1200 SCD transplant cases from related and alternate donor sources [22]. Among the HLA-ID sibling donor cohorts, the rates of overall survival in the Center for International Blood and Marrow Transplant Research (N = 412) and Eurocord/European Blood and Marrow Transplant (EBMT; N = 487) registries were 91% and 95%, respectively [22]. In a separate analysis comparing outcomes in 160 children with SCD who received HLA-ID sibling BMT and umbilical cord blood transplantation between 1994 and 2005 in the United States and Europe, there was no statistically significant difference in overall survival and EFS between these 2 donor sources [23]. Moreover, the combined 6-year disease-free survival rate was 92%.

These retrospective registry data also were reviewed critically by an international expert panel on behalf of the EBMT Inborn Error and EBMT Paediatric Working Parties [24] and the following recommended for HLA-ID HCT for children:

- Young patients with symptomatic SCD who have an HLA-ID sibling donor should be transplanted as early as possible, preferably at preschool age.
- Unmanipulated BM or umbilical cord blood (whenever available) from HLA-ID sibling donors are the recommended stem cell source.

However, an alternate view recently expressed by SCD experts is that additional research is still needed to
address the potential risks of this therapy, such as failure of engraftment and chronic GVHD before HCT can be widely used [25]. The objective of reducing the risk of HCT in children with SCD has been largely accomplished when an HLA-ID sibling donor is used, which challenges this opinion. The 2-year transplant-related mortality risk after HLA-ID sibling donor HCT appears very similar to the risk in children with SCD who receive standard supportive care. This notion is further strengthened by a recent report that described a cohort of 469 children and adults with SCD in Belgium in which the 15-year survival rate after transplantation compared with supportive care was not significantly different (mortality rate of .38 and .34/100 patient-years, respectively, in supportive care and HCT) [36].

There is limited but growing transplant experience in adults with SCD. The eligibility criteria used in 2 active trials are shown in Table 3. There is a potential for a wider acceptability of HCT in adults with severe SCD for several reasons. First, unlike the experience in childhood during which survival to adulthood improved significantly after the institution of comprehensive care, the mortality rate among adults has changed very little in the past several decades [29,30]. Patients with symptomatic SCD who participated in the Multicenter Study of Hydroxyurea represent a cohort that mirrors adult patients referred for HCT [31]. The annual mortality rate in the long-term (17.5 years) follow-up cohort from the Multicenter Study of Hydroxyurea was 4.4 per 100 person-years. The mortality rate was quite similar across groups who received HU for <5 years, 5 to <10 years, and 10 to <15 years. After roughly 13 years of continuous HU treatment, however, the mortality rate declined to 2.5% per year and 2.25% per year in the groups of patients treated for the longest periods of time. Another recent report of 534 adults with SCD showed 25% mortality at the end of the 10-year study. The mortality was even higher among those

### Table 2

Clinical Outcome of HLA-ID Sibling HCT for Children with SCD

<table>
<thead>
<tr>
<th>Center</th>
<th>Preparative Regimen</th>
<th>GVHD Prophylaxis</th>
<th>n</th>
<th>Age Range (yr)</th>
<th>Follow-Up</th>
<th>Death (nos)</th>
<th>Complications</th>
<th>IST</th>
<th>GVHD</th>
<th>Donor Chimerism</th>
</tr>
</thead>
</table>
| Rome [Lucarelli, 2014]  | BU 14 mg/kg, CY 200 mg/kg, rATG 10 mg/kg, 
|                         | rHU 150 mg/kg/m²  | CsA, MTX, pred | 40 | 2-17           | 1-10      | 3 (2.5, 6, 15) | 3 deaths from GVHD | 1 of 40 | 17.5% aGVHD, 5% cGVHD | 25-100% |
| Brussels [Dedeken, 2014]| BU 13-18 mg/kg, CY 200 mg/kg, 
|                         | rATG (10-20 mg/kg), 
|                         | rHU              | CsA, MTX or MMF (UCB) | 50 | 1.7-15.3 .4-21.3 | 2 (6, 78) | 4, sepsis, 1 IMI, seizures 21%, 6, PRES | 1 of 50 | 20.5% aGVHD, 20% cGVHD | 15-100% |
| New York [Bhata, 2014] | BU 12.8-16 mg/kg, 
|                         | CY 200 mg/kg, 
|                         | rHU              | Tacrolimus, MMF | 18 | 2.3-20.2 .4-7.5 | None | ICH in 1, PRES in 1, CMV react in 4 | 1 death from sepsis, 1 AIHA | None | 17% aGVHD, 11% cGVHD | Mean 88% |
| Mississippi [Majumdar, 2010] | BU 14 mg/kg, CY 200 mg/kg, 
|                         | ATG 90 mg/kg     | CsA, Pred | 10 | 2.8-16.3 .2-9.9 | 1 | 8 VOD, 16% seizures, 2 ICH | None | 12% aGVHD, 1 death from cGVHD | 62-100% |
| Atlanta [McPherson, 2011] | BU 14 mg/kg, CY 200 mg/kg, 
|                         | ATG 90 mg/kg     | CsA, MTX or MMF | 27 | 3.3-17.4 .1-10 | 1 (3) | 8 VOD, 16% seizures, 2 ICH | None | 7% Grades I-II aGVHD, 50% (BU) and 36% (Treo) | 1 y |
| Pavia [Strocchio, 2015] | BU 16 mg/kg, TT 10 mg/kg, 
|                         | Flu 160 mg/m², 
|                         | or Treo 14 gm/m², 
|                         | Flu 160 mg/m², ATG | CsA, MTX or MMF | 30 | 1.7-18.8 .5-14 | None | Stomatitis (43%), GI toxicity (17%); no VOD | None | 7% aGVHD, 50% (BU) and 36% (Treo) | 1 y |
| United States [King, 2015] | Alem 48 mg, 
|                         | Flu 140-150 mg/m², 
|                         | melphalan 140 mg/m² | CsA or tacrolimus | 43 | 3-20.3 .75-11.83 | 3 (11, 18, 21) | 3 deaths from GVHD | 19% by 1 y | 23% aGVHD, 13.4% cGVHD | 29-100% |

IST indicates immunosuppressive therapy; CY, cyclophosphamide; rATG, rabbit ATG; CsA, cyclosporine; MTX, methotrexate; pred, prednisone; aGVHD, acute GVHD; cGVHD, chronic GVHD; MMF, mycophenolate mofetil; UCB, umbilical cord blood; IMI, invasive mold infection; PRES, posterior reversible encephalopathy syndrome; ICH, intracranial hemorrhage; CMV, cytomegalovirus; AIHA, autoimmune hemolytic anemia; VOD, veno-occlusive disease; Treo, treosulfan; ceGVHD, chronic extensive GVHD; TT, thiotepa; GI, gastrointestinal.

### Table 3

Indications of HCT in Adult Recipients with SCD

| Age, 15-40 yr with SCD and 1 or more of the following  
| Clinical significance of neurologic event (stroke) or any neurologic deficit lasting > 24 hr  
| History of 2 or more episodes of acute chest syndrome in the 2-yr period preceding HCT despite the institution of supportive care measures (ie, asthma therapy and/or HU)  
| History of 3 or more severe pain crises per year in the 2-yr period preceding enrollment despite the institution of supportive care measures (ie, a pain management plan and/or treatment with HU)  
| Administration of regular RBC transfusion therapy, defined as receiving 8 or more transfusions per year for >1 yr to prevent vaso-occlusive clinical complications (ie, pain, stroke, and acute chest syndrome)  
| An echocardiographic finding of tricuspid valve regurgitant jet ≥ 2.7 m/s |
having >4 pain crises per year or those with a higher organ severity score [30]. Thus, if the 2-year mortality probability after HCT in adults is <20%, it is very likely that transplantation will confer a long-term survival advantage in adult recipients.

Doppler transthoracic echocardiography has been validated in several cohorts as a screening tool to identify high-risk patients for early mortality. In 3 large screening studies approximately 30% of patients had a tricuspid valve regurgitant jet velocity (TRV) > 2.5 m/s and 10% had a TRV > 3 m/s. In all epidemiologic studies performed to date, the risk ratio of early death in adults with a TRV > 2.5 m/s ranged from 9.24- to 15.9-fold [32-34]. More recently, a larger cohort of 483 patients was screened in the Walk-PHASST (Walk-Treatment of Pulmonary Hypertension and Sickle Cell Disease with Sildenafil Therapy) screening study [35,36]. In this cohort, 67 participants (9.1%) had a TRV > 3 m/s that was associated with a 2-year mortality of 11.9%. Using a 2-variable positive predictive value assessment of 2-year mortality risk in this same cohort, it was possible to identify very high-risk patients. Subjects who had a combination of TRV > 3 m/sec with WBC counts > 13,500 or chronic transfusion therapy had a 2-year mortality rate that exceeded 20% [37]. Finally, 43 of 240 subjects from a cohort of adults with SCD died between 2000 and 2005, with a median survival of 40 years [38]. The authors concluded that HU protected from acute sickle-related events but not from cardiopulmonary complications, which were the leading cause of death. Thus, in selected groups of adults with SCD, even if the 2-year probability of transplant-related mortality is approximately 20%, survival in the short term compared with those who lack a donor might be acceptable.

**TABLE 4**

Recent Results of HLA-Matched HCT in Adults with SCD

<table>
<thead>
<tr>
<th>Center</th>
<th>Preparative Regimen</th>
<th>GVHD Prophylaxis</th>
<th>n</th>
<th>Age Range (yr)</th>
<th>Follow-Up (yr)</th>
<th>Death (mo)</th>
<th>Complications</th>
<th>IST</th>
<th>GVHD</th>
<th>Donor Chimerism</th>
</tr>
</thead>
<tbody>
<tr>
<td>NHLBI (Hsieh, 2009, 2014)</td>
<td>Alem 1 mg/kg, TBI 300 cGy</td>
<td>Sirolimus</td>
<td>30</td>
<td>17-65</td>
<td>1.8-6</td>
<td>1 (ICH)</td>
<td>GR (n = 4)</td>
<td>11 of 26</td>
<td>None</td>
<td>Median</td>
</tr>
<tr>
<td>France (Kuentz, 2011)</td>
<td>BU 14 mg/kg, CY 200 mg/kg, CsA, MTX</td>
<td>Sirolimus</td>
<td>15</td>
<td>16-27.5</td>
<td>1-16.1</td>
<td>1 (ICH)</td>
<td>SDH (n = 1), seizures</td>
<td>—</td>
<td>8 aGVHD</td>
<td>75-100%</td>
</tr>
</tbody>
</table>

NHLBI indicates National Heart, Lung, Blood Institute; TBI, total body irradiation; GR, graft rejection; SDH, subdural hematoma.

**SUMMARY**

Just as refinement in supportive care for SCD has improved the likelihood of survival to adulthood, results after HLA-ID sibling HCT have also improved significantly in the past 15 years. In addition, the goal of cure is achieved in 90% or more of transplant recipients. Because there appears to be very little if any survival disadvantage after HCT compared with those who receive supportive care, a broadened view about transplant eligibility is warranted [45]. The role of HCT in adults with symptomatic SCD is less well defined because of the small number of published reports; however, projections based on the risk of early mortality in adults with severe SCD also warrants broader endorsement of HCT as a therapeutic option, particularly when investigated in National Institutes of Health–funded prospective clinical trials.

**ACKNOWLEDGMENTS**

Financial disclosure: MCW is medical director for the ViaCord Processing Laboratory and AllCells, Inc. He is a consultant for bluebird bio, Inc, Sangamo Biosciences, Inc and Bayer.

**REFERENCES**


